HC Wainwright Issues Positive Outlook for Agenus Earnings

Agenus Inc. (NASDAQ:AGEN) – HC Wainwright increased their Q3 2026 earnings per share estimates for Agenus in a report released on Friday, August 7th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will post earnings of $0.05 per share for the quarter, up from their prior forecast of $0.03. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Agenus’ current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Agenus’ Q4 2026 earnings at $0.05 EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.19) EPS, FY2028 earnings at ($0.49) EPS, FY2029 earnings at ($0.58) EPS and FY2030 earnings at ($0.31) EPS.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Monday, May 11th. The biotechnology company reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.10 by ($1.08). The company had revenue of $33.74 million during the quarter, compared to analyst estimates of $129.50 million. Agenus had a negative return on equity of 45.12% and a net margin of 69.33%.

Other research analysts also recently issued research reports about the stock. B. Riley Financial restated a “buy” rating and set a $14.00 price objective (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. Wall Street Zen upgraded shares of Agenus from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Zacks Research downgraded Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Weiss Ratings upgraded Agenus from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $22.00.

Agenus Price Performance

NASDAQ:AGEN opened at $7.00 on Tuesday. Agenus has a one year low of $2.71 and a one year high of $8.85. The company has a fifty day moving average price of $4.54 and a 200 day moving average price of $3.84. The stock has a market cap of $313.25 million, a P/E ratio of 2.71 and a beta of 1.40.

Institutional Investors Weigh In On Agenus

A number of hedge funds have recently made changes to their positions in the company. LPL Financial LLC lifted its holdings in Agenus by 20.3% during the 4th quarter. LPL Financial LLC now owns 23,326 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 3,943 shares during the last quarter. EP Wealth Advisors LLC bought a new stake in Agenus during the fourth quarter worth about $31,000. Jump Financial LLC bought a new stake in Agenus during the second quarter worth about $55,000. R Squared Ltd acquired a new stake in shares of Agenus during the fourth quarter worth approximately $41,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Agenus during the third quarter worth approximately $54,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.